Mena-Vázquez Natalia, Manrique Arija Sara, Rojas-Giménez Marta, Raya-Álvarez Enrique, Velloso-Feijoó María Luisa, López-Medina C, Ramos-Giraldez Consuelo, Godoy-Navarrete Francisco Javier, Redondo-Rodríguez Rocío, Cabezas-Lucena Alba María, Morales-Águila M, Romero-Barco C M, Fernández-Nebro Antonio
Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.
Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; UGC de Reumatología, Hospital Regional Universitario de Málaga, Málaga, España.
Reumatol Clin (Engl Ed). 2021 Mar 20;18(7):422-8. doi: 10.1016/j.reuma.2021.02.009.
To describe whether rheumatic inflammatory diseases (RID) are associated with a higher risk of hospitalization and/or mortality from COVID-19 and identify the factors associated with hospitalization and mortality in RID and COVID-19 in different Hospitals in Andalusia.
Design: Multicentre observational case-control study.
RID and COVID-19 from different centres in Andalusia.
patients without RIS matched by sex, age and CRP-COVID. Protocol A list of patients with PCR for COVID-19 was requested from the microbiology service from March 14 to April 14, 2020. The patients who had RID were identified and then consecutively a paired control for each case. Variables The main outcome variable was hospital admission and mortality from COVID-19. Statistical analysis Bivariate followed by binary logistic regression models (DV: mortality/hospital admission).
One hundred and fifty-six patients were included, 78 with RID and COVID-19 and 78 without RID with COVID-19. The patients did not present characteristics of COVID-19 disease different from the general population, nor did they present higher hospital admission or mortality. The factor associated with mortality in patients with RID was advanced age (OR [95% CI], 1.1 [1.0-1.2]; p = 0.025), while the factors associated with hospitalization were advanced age (OR [95% CI], 1.1 [1.0-1.1]; p = 0.007) and hypertension (OR [95% CI], 3.9 [1.5-6.7]; p = 0.003).
Mortality and hospital admission due to COVID-19 do not seem to increase in RID. Advanced age was associated with mortality in RID and, in addition, HTN was associated with hospital admission.
描述风湿性炎症性疾病（RID）是否与COVID-19导致的更高住院风险和/或死亡率相关，并确定安达卢西亚不同医院中RID合并COVID-19患者住院和死亡的相关因素。
设计：多中心观察性病例对照研究。
来自安达卢西亚不同中心的RID合并COVID-19患者。
按性别、年龄和COVID-19相关C反应蛋白匹配的无RID患者。方案：向微生物学服务部门索要2020年3月14日至4月14日期间进行COVID-19聚合酶链反应检测的患者名单。确定患有RID的患者，然后为每个病例连续选取一名配对对照。变量：主要结局变量是COVID-19导致的住院和死亡。统计分析：双变量分析，随后进行二元逻辑回归模型（因变量：死亡率/住院率）。
纳入156例患者，78例为RID合并COVID-19患者，78例为无RID的COVID-19患者。这些患者未表现出与普通人群不同的COVID-19疾病特征，也未表现出更高的住院率或死亡率。RID患者死亡的相关因素是高龄（比值比[95%置信区间]，1.1[1.0 - 1.2]；p = 0.025），而与住院相关的因素是高龄（比值比[95%置信区间]，1.1[1.0 - 1.1]；p = 0.007）和高血压（比值比[95%置信区间]，3.9[1.5 - 6.7]；p = 0.003）。
RID患者因COVID-19导致的死亡率和住院率似乎并未增加。高龄与RID患者的死亡率相关，此外，高血压与住院率相关。
